Search Results

InflaRx N.V. (Nasdaq: IFRX) announced today that GOHIBIC (vilobelimab) has been selected by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services, as one of three investigational therapies to be assessed in a Phase 2 clinical platform study exploring potential new options for the treatment of acute respiratory distress syndrome (ARDS).

InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today hosted a virtual R&D event focused on the company’s oral small molecule C5aR inhibitor, INF904.

InflaRx N.V. announced financial results for the three months ended March 31, 2024, and provided an operating update.

InflaRx N.V., a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, announced the appointment of Jan Medina, CFA, as Vice President and Head of Investor Relations of InflaRx.

InflaRx N.V. announced that it will host a conference call this Thursday, March 21, 2024 at 8:00 am ET / 1:00 pm CET to discuss the Company’s anticipated development plans for INF904, InflaRx’s orally available C5aR inhibitor with best-in-class potential.

InflaRx N.V. today announced that the Company will participate in the Capital One Securities 1st Annual Biotech/Biopharma Disrupters Event to be held in New York City.